TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05544786
Drug: Nirmatrelvir/Ritonavir
Normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single oral dose of nirmatrelvir/ritonavir mixed in infant formula under fasted condition
Study: NCT05544786
Drug: Nirmatrelvir/ritonavir
Normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fasted condition
Study: NCT05544786
Drug: Nirmatrelvir/ritonavir
Normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fed condition
Study: NCT05020392
Drug: BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTK inhibitor from enrollment to more than 90 days after CAR-T-CD19 infusion. Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
Study: NCT05020392
Drug: Fludarabine-based chemotherapy + CAR-T-CD19 Cells
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine-based lymphodepletion chemotherapy was followed by CART19 infusion at a dose of 1x10\^6/kg on day 0 and day 1 respectively.
Study: NCT05275647
Drug: BOTOX 100U in normal saline
Normalized name: NS-2
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LESW with 3000 shocks, frequency of 3 pulses per second, and maximum total energy flow density 0.25 mJ/mm2 , and followed by intravesical BoNT-A 100U instillation in 30ml normal saline retained in the bladder for 2 hours, every one week for 4 times.
Study: NCT05992597
Drug: ZR2 RDHAP
Normalized name: DHAP
DrugBank: Dihydroxyacetone phosphate (DB04326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.
Study: NCT00345137
Drug: Ng-monomethyl-L-arginine (drug)
Normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05024253
Drug: Tranexamic acid injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: . TXA, a lysine analogue, reversibly binds to the plasminogen lysine receptors and thereby blocks plasminogen from binding to fibrin (tPA can only activate fibrin-bound plasminogen and produce plasmin responsible for cleaving fibrin molecule and dissolving the blood clot)
Study: NCT05767632
Drug: Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test)
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet Mirfenacin MR contains Solifenacine succinate 5 mg \& Mirabegron 50 mg orally administrated followed by 240 ml of water
Study: NCT06315699
Drug: Clemastine Fumarate Tablets
Normalized name: Clemastine Fumarate Tablets
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose was administered 2mg once daily in a double-blind random crossover method
Study: NCT05966324
Drug: baxdrostat
Normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxdrostat is an aldosterone synthase inhibitor
Study: NCT05405192
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: First four cycles of Dostarlimab will be given intravenously (IV) on day 1 of each of the 21-day cycle at a dose of 500 milligrams (mg). The next 16 cycles of Dostarlimab will be given on day 1 of each of the 42-day cycles at a dose of 1,000 mg.
Study: NCT06537349
Drug: 3% Diquafosol tetrasodium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in OK lens related dry eye
Study: NCT04779255
Drug: Control Arm (Paracetamol)
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Photodynamic therapy of vertex with 1g of paracetamol intake 1 hour before cold water is applied during the session.
Study: NCT05608044
Drug: Botensilimab
Normalized name: Botensilimab
DrugBank: Botensilimab (DB16651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.
Study: NCT05608044
Drug: Balstilimab
Normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody.
Study: NCT04695860
Drug: Burosumab
Normalized name: Burosumab
DrugBank: Burosumab (DB14012)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Q4w, 1mg/kg Body weight, s.c.
Study: NCT04768465
Drug: Pyridostigmine, Prednisone, Tacrolimus
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Prednisone is administrated with an initial dose of 0.25mg/kg/d and started to tamper with the achievement of MMS or the presence of any intolerable side effects. The rate of tampering is considered by the physician, usually no more than 5mg/month. If the participants failed to maintain MMS, dose of prednisone should be increased 5mg/week to 0.25mg/kg/d and maintained until MMS reached again. After MMS sustained for 1 month, prednisone dose would be tapered again with 2.5mg/month. Calcium and potassium supplements and gastric mucosa protectors could be addressed to avoid any adverse effects of prednisone. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
Study: NCT04768465
Drug: Pyridostigmine, Tacrolimus
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of tacrolimus should be initiated based on CYP3A5\*3 polymorphism and adjusted to achieve blood trough concentration of 4.8-10.0 ng/ml. Treatment regimens are determined based on the physician's judgment and preferences of the patients. This study was observational and do not change the clinical course of patients.
Study: NCT05925023
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral administration, 1-3 mg/d, sirolimus plasma concentration: 4-15 ng/mL
Study: NCT06664125
Drug: JMKX003002 will be administered orally
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets for oral administration.
Study: NCT06664125
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets for oral administration.
Study: NCT02523092
Drug: Acthar gel
Normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acthar gel given IM or SQ as per package insert
Study: NCT05415254
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol supplementation orally
Study: NCT04822818
Drug: BEVA+SOC
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1) SOC : patients will receive the best of standard of care including corticosteroids, anticoagulant, antibiotics and tociluzimab
Study: NCT05047133
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
Study: NCT01949766
Drug: Glycerol phenylbutyrate
Normalized name: Glycerol Phenylbutyrate
DrugBank: Glycerol phenylbutyrate (DB08909)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05881486
Drug: Ondansetron 8mg
Normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg Ondansetron+100 ml normal saline
Study: NCT05881486
Drug: Fosaprepitant 150 mg
Normalized name: fosaprepitant 150 MG
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg fosaprepitant +100 ml normal saline
Study: NCT04910386
Drug: Envafolimab plus Gemcitabine&Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Envafolimab a programmed death ligand immune check inhibitor Per Investigator decision
Study: NCT04910386
Drug: Gemcitabine&Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The standard of care for the patients with unresectable/metastatic biliary tract cancer
Study: NCT05369377
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 80mg po qd 6 weeks
Study: NCT05369377
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.
Study: NCT05369364
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 80mg qd po, 6 consecutive weeks
Study: NCT05369364
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)
Study: NCT05350215
Drug: Atomoxetine Oral Capsule [Strattera]
Normalized name: atomoxetine Oral Capsule [Strattera]
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep
Study: NCT05382741
Drug: Durvalumab Injection for intravenous use 500 mg vial solution for infusion
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MEDI4736
Study: NCT05382741
Drug: Regorafenib 30 mg capsules
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BAY73-4506
Study: NCT05559905
Drug: Molnupiravir
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
Study: NCT05889793
Drug: Emetine Hydrochloride
Normalized name: Emetine Hydrochloride
DrugBank: Emetine (DB13393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To administer Emetine Hydrochloride 6mg orally for 10 consecutive days to evaluate the efficacy and safety of emetine for symptomatic Covid-19 patients.
Study: NCT06368843
Drug: Gargle with ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients asked to gargling with ketamine solution in the preoperative waiting area after explain the whole procedure and the goals of the study.
Study: NCT05151510
Drug: Lidocaine patch 5%
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Will place lidocaine patch onto skin overlaying point of maximal tenderness
Study: NCT05503979
Drug: Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]
Normalized name: sofosbuvir 400 MG / velpatasvir 100 MG [Epclusa]
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tab every 24 hrs for 12 weeks
Study: NCT03621904
Drug: Hormonal Antineoplastics
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy used for treatment in endometrial cancer patients
Study: NCT05790044
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intra-oral infra-orbital nerve block with bupivacaine alone
Study: NCT05790044
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intra-oral infra-orbital nerve block with bupivacaine and clonidine
Study: NCT06400589
Drug: tanfanercept
Normalized name: Tanfanercept
DrugBank: Tanfanercept (DB19142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF inhibitor
Study: NCT05034042
Drug: Fezolinetant
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04961281
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: injection of Dexmedetomidine ( 10 microgram/kg) + 10 cc saline injection nearby median nerve as hydro-dissection
Study: NCT04961281
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of triamcinolone ( 40 mg) + 10 cc saline injection nearby median nerve as hydro-dissection
Study: NCT04615624
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide, a loop diuretic
Study: NCT04949516
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin is discontinued the day after drug-eluting stent implantation
Study: NCT04949516
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine is started the day after drug-eluting stent implantation
Study: NCT06182098
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg/kg, with a maximum of 25mg
Study: NCT06182098
Drug: Prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.15mg/kg, with a maximum of 10mg
Study: NCT05257590
Drug: Nivolumab Injection [Opdivo]
Normalized name: nivolumab Injection [Opdivo]
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
Study: NCT05650476
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT00000696
Drug: Interferon alfa-2a
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000696
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06504199
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No dose adjustment of Obinutuzumab is allowed.
Study: NCT06504199
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib was allowed to be titrated to 80 mg bid or 80 mg qd
Study: NCT06504199
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide was allowed to be titrated to 15 mg/day (induction phase) or 5 mg/day (maintenance phase).
Study: NCT06504199
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The specific dose is determined by the investigator according to the actual situation of the patient.
Study: NCT00002108
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002108
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001059
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00001059
Drug: Bleomycin sulfate
Normalized name: Bleomycin Sulfate
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001059
Drug: Vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06005532
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab injection 40 mg / 0.8 ml
Study: NCT06005532
Drug: Humira
Normalized name: Humira
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab injection 40 mg / 0.4 ml
Study: NCT05359315
Drug: Interferon-Gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study: NCT05653245
Drug: RGD Peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adhesion molecules
Study: NCT00001033
Drug: Ethambutol hydrochloride
Normalized name: Ethambutol Hydrochloride
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001033
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001033
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001033
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001033
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05871424
Drug: buprenorphine patch group
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mcg/h buprenorphine patch will be applied preoperatively
Study: NCT05237505
Drug: Oxygen gas
Normalized name: oxygen Gas for Inhalation
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose of nocturnal oxygen in all participants in the oxygen therapy arm will be 2 liters/minute. Patients with daytime hypoxemia, measured as sustained desaturations below 89% during wake time and/or arterial blood PO2 ≤ 55 mmHg, will be excluded from this study (as specified in the exclusion criteria) for ethical reasons since withholding oxygen in hypoxemic patients would be at odds with standard of care.
Study: NCT04254692
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the intervention group will receive intraoperative injection of Liposomal bupivacaine mixed with Bupivacaine to the abdominal wall.
Study: NCT05999630
Drug: Artificial Tears Methylcellulose
Normalized name: ARTIFICIAL TEARS METHYLCELLULOSE
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will self-administer the artificial tears according to the schedule.
Study: NCT06206096
Drug: oxaliplatin+capecitabine+bevacizumab+PD-1 antibody
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oxaliplatin will be administered once every 3 weeks at a dose of 130 mg/m2; Capecitabine will be taken orally at a dose of 1g/m2 twice daily for continuous oral administration over 14 days; Bevacizumab will be administered intravenously every 3 weeks at a dose of 7.5 mg/kg; PD-1 antibody was given due to different types.
Study: NCT05497739
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Fu 1 g/m\^2 on Days 1, 8, 15, and 22; Albumin-paclitaxel 80-100 mg/time on Days 1, 8, 15, and 22; Cisplatin 25 mg/m\^2 on Days 4, 11, 18, and 25; Interleukin-2 2 million units/time on Days 4, 11, 18, and 25.
Study: NCT06315972
Drug: clemastine (8 mg/day)
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: add-on clemastine (8 mg/day) + aerobic exercise training
Study: NCT05027386
Drug: Apatinib, Irinotecan, Temozolomide
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The enrolled patients diagnosed with recurrent or refractory pediatric neuroblastoma received apatinib combined with IT regimen chemotherapy, the treatment including combination therapy phase and monotherapy maintenance phase.
Study: NCT04923594
Drug: mazindol extended release
Normalized name: clorazepate / mazindol Extended Release Oral Tablet
DrugBank: Mazindol (DB00579)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosed orally, once daily for up to 3 weeks
Study: NCT00002081
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002081
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05088330
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treatment with D-VRD in NDMM
Study: NCT06345261
Drug: DiphenhydrAMINE 50 Mg/mL Injectable Solution
Normalized name: diphenhydrAMINE 50 mg/mL injectable solution
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of Diphenhydramine 50 Mg/mL
Study: NCT06345261
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of saline
Study: NCT06534047
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will receive individualized NRT treatment through the advice of their study physician for 6 weeks. The study physician, in discussion with the participant, will decide the type, dosage, and combination of NRT to provide to the participant.~NRT provided can include:~* Patch (7mg, 14mg, and 21mg)~* Gum (2mg)~* Lozenge (2mg)~* Inhaler (10mg; 4mg of nicotine delivered)
Study: NCT06190470
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis product is from the extraction of the powdered, dried and mature pistillate inflorescences of Cannabis sativa L. containing THC 30mg/ml.
Study: NCT04808791
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase I inhibitor.